Education
About Us
Working with TipRanks
Follow Us
Novartis AG (DE:NOT)
XETRA:NOT
NOT Stock Chart & Stats
€143.20
€0.00(0.00%)
At close: 4:00 PM EST
€143.20
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€79.74 - €144.12
Previous CloseN/A
Volume24.84K
Average Volume (3M)909.00
Market Cap
€271.38B
Enterprise Value€334.29B
Total Cash (Recent Filing)€11.58B
Total Debt (Recent Filing)€37.01B
Price to Earnings (P/E)22.5
Beta0.33
Next Earnings
Apr 28, 2026EPS Estimate
1.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.74
Shares Outstanding2,112,421,900
10 Day Avg. Volume1,167
30 Day Avg. Volume909
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)5.81
Price to Sales (P/S)4.69
P/FCF Ratio14.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€129.76Price Target Upside-9.39% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)9.75
Revenue Forecast (FY)€63.20B
Bulls Say, Bears Say
Bulls Say
Avidity Acquisition PotentialThe Avidity acquisition adds neuromuscular assets viewed as potential multi-billion dollar opportunities that could drive substantial long-term growth if clinical and commercial milestones are achieved.
Late-stage Pipeline DepthA diversified mid-to-late-stage pipeline with multiple upcoming trial readouts offers a clear catalyst path that could materially shift the product mix and reduce reliance on expiring franchises.
Product Launches And Commercial UptakeRecent launches such as Pluvicto, Scemblix and Leqvio have shown encouraging early commercial uptake, supporting near-term revenue growth as older drugs lose exclusivity.
Bears Say
Clinical Readout DelaysDelays to several late-stage development programs push out expected clinical readouts, reducing near-term catalysts and deferring potential approvals.
Guidance And Margin PressureCompany guidance points to lower operating income and higher acquisition-related financial costs, indicating potential near-term margin dilution and pressure on earnings.
Patent ExpirationsSignificant patent expirations on key medicines remain a major overhang that could erode sales if new launches do not quickly replace lost volumes.
Novartis AG News
NOT FAQ
What was Novartis AG’s price range in the past 12 months?
Novartis AG lowest stock price was €79.74 and its highest was €144.12 in the past 12 months.
What is Novartis AG’s market cap?
Novartis AG’s market cap is €271.38B.
When is Novartis AG’s upcoming earnings report date?
Novartis AG’s upcoming earnings report date is Apr 28, 2026 which is in 55 days.
How were Novartis AG’s earnings last quarter?
Novartis AG released its earnings results on Feb 04, 2026. The company reported €1.736 earnings per share for the quarter, beating the consensus estimate of €1.701 by €0.035.
Is Novartis AG overvalued?
According to Wall Street analysts Novartis AG’s price is currently Overvalued.
Does Novartis AG pay dividends?
Novartis AG does not currently pay dividends.
What is Novartis AG’s EPS estimate?
Novartis AG’s EPS estimate is 1.8.
How many shares outstanding does Novartis AG have?
Novartis AG has 2,112,421,900 shares outstanding.
What happened to Novartis AG’s price movement after its last earnings report?
Novartis AG reported an EPS of €1.736 in its last earnings report, beating expectations of €1.701. Following the earnings report the stock price went up 1.336%.
Which hedge fund is a major shareholder of Novartis AG?
Currently, no hedge funds are holding shares in DE:NOT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
NOT Stock 12 Month Forecast
Average Price Target
€129.76
▼(-9.39% Downside)
Technical Analysis
Options Prices
Currently, No data available
---